Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)

PURPOSE: To determine the pathologic complete response (pCR) rate in estrogen receptor (ER) –positive primary breast cancer triaged to chemotherapy when the protein encoded by the MKI67 gene (Ki67) level was > 10% after 2 to 4 weeks of neoadjuvant aromatase inhibitor (AI) therapy. A second object...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Ellis, Matthew J., Suman, Vera J., Hoog, Jeremy, Goncalves, Rodrigo, Sanati, Souzan, Creighton, Chad J., DeSchryver, Katherine, Crouch, Erika, Brink, Amy, Watson, Mark, Luo, Jingqin, Tao, Yu, Barnes, Michael, Dowsett, Mitchell, Budd, G. Thomas, Winer, Eric, Silverman, Paula, Esserman, Laura, Carey, Lisa, Ma, Cynthia X., Unzeitig, Gary, Pluard, Timothy, Whitworth, Pat, Babiera, Gildy, Guenther, J. Michael, Dayao, Zoneddy, Ota, David, Leitch, Marilyn, Olson, John A., Allred, D. Craig, Hunt, Kelly
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2017
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5455353/
https://ncbi.nlm.nih.gov/pubmed/28045625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.69.4406
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados